Altmarc

Altmarc Pharmaceuticals is a clinical-stage biotechnology company focused on the development of transformative therapies for rare kidney diseases. The company's lead program, ALM-001, is an investigational oral small molecule designed to treat Alport syndrome, a genetic disorder characterized by progressive kidney disease and hearing loss. ALM-001 functions as a chemical chaperone to stabilize the type IV collagen network, addressing the underlying cause of the disease. Founded by industry veterans with significant experience in orphan drug development, Altmarc aimed to fill a critical gap in the treatment landscape for Alport syndrome. In September 2020, the company was acquired by Travere Therapeutics (formerly Retrophin) for an upfront payment of $10 million plus potential milestones. This acquisition integrated Altmarc's lead asset into Travere's growing pipeline of rare nephrology treatments.